Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors.

Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A.

J Clin Endocrinol Metab. 2005 Apr;90(4):2179-86. Epub 2005 Jan 11.

PMID:
15644399
2.

Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.

Gejman R, Batista DL, Zhong Y, Zhou Y, Zhang X, Swearingen B, Stratakis CA, Hedley-Whyte ET, Klibanski A.

J Clin Endocrinol Metab. 2008 Oct;93(10):4119-25. doi: 10.1210/jc.2007-2633. Epub 2008 Jul 15.

3.

Cyclic AMP stimulates MEG3 gene expression in cells through a cAMP-response element (CRE) in the MEG3 proximal promoter region.

Zhao J, Zhang X, Zhou Y, Ansell PJ, Klibanski A.

Int J Biochem Cell Biol. 2006;38(10):1808-20. Epub 2006 May 17.

PMID:
16793321
4.

A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells.

Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Klibanski A.

J Clin Endocrinol Metab. 2003 Nov;88(11):5119-26.

PMID:
14602737
5.

Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.

Sheng X, Li J, Yang L, Chen Z, Zhao Q, Tan L, Zhou Y, Li J.

Oncol Rep. 2014 Jul;32(1):277-85. doi: 10.3892/or.2014.3208. Epub 2014 May 22.

PMID:
24859196
6.

Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression.

Zhang X, Gejman R, Mahta A, Zhong Y, Rice KA, Zhou Y, Cheunsuchon P, Louis DN, Klibanski A.

Cancer Res. 2010 Mar 15;70(6):2350-8. doi: 10.1158/0008-5472.CAN-09-3885. Epub 2010 Feb 23.

7.

Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.

Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC Jr, Yu Y.

Cancer Res. 2003 Jul 15;63(14):4174-80.

8.

Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions.

Zhang X, Rice K, Wang Y, Chen W, Zhong Y, Nakayama Y, Zhou Y, Klibanski A.

Endocrinology. 2010 Mar;151(3):939-47. doi: 10.1210/en.2009-0657. Epub 2009 Dec 23.

9.

Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas.

Cheunsuchon P, Zhou Y, Zhang X, Lee H, Chen W, Nakayama Y, Rice KA, Tessa Hedley-Whyte E, Swearingen B, Klibanski A.

Am J Pathol. 2011 Oct;179(4):2120-30. doi: 10.1016/j.ajpath.2011.07.002. Epub 2011 Aug 24.

10.

MEG3 noncoding RNA: a tumor suppressor.

Zhou Y, Zhang X, Klibanski A.

J Mol Endocrinol. 2012 Apr 2;48(3):R45-53. doi: 10.1530/JME-12-0008. Print 2012 Jun. Review.

11.

Expression analysis of GADD45γ, MEG3, and p8 in pituitary adenomas.

Binse I, Ueberberg B, Sandalcioglu IE, Flitsch J, Luedecke DK, Mann K, Petersenn S.

Horm Metab Res. 2014 Aug;46(9):644-50. doi: 10.1055/s-0034-1383566. Epub 2014 Aug 15.

PMID:
25126861
12.

Alternative splicing and imprinting control of the Meg3/Gtl2-Dlk1 locus in mouse embryos.

Croteau S, Charron MC, Latham KE, Naumova AK.

Mamm Genome. 2003 Apr;14(4):231-41.

PMID:
12682775
13.

Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour.

Astuti D, Latif F, Wagner K, Gentle D, Cooper WN, Catchpoole D, Grundy R, Ferguson-Smith AC, Maher ER.

Br J Cancer. 2005 Apr 25;92(8):1574-80.

14.

Loss of expression of the growth inhibitory gene GADD45gamma, in human pituitary adenomas, is associated with CpG island methylation.

Bahar A, Bicknell JE, Simpson DJ, Clayton RN, Farrell WE.

Oncogene. 2004 Jan 29;23(4):936-44.

PMID:
14647444
15.

Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas.

Qian ZR, Sano T, Yoshimoto K, Yamada S, Ishizuka A, Mizusawa N, Horiguchi H, Hirokawa M, Asa SL.

Lab Invest. 2005 Apr;85(4):464-73.

16.

Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma.

Revill K, Dudley KJ, Clayton RN, McNicol AM, Farrell WE.

Endocr Relat Cancer. 2009 Jun;16(2):537-48. doi: 10.1677/ERC-09-0008. Epub 2009 Feb 13.

17.

Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma.

Benetatos L, Dasoula A, Hatzimichael E, Georgiou I, Syrrou M, Bourantas KL.

Clin Lymphoma Myeloma. 2008 Jun;8(3):171-5. doi: 10.3816/CLM.2008.n.021.

PMID:
18650181
18.

Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island.

Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE.

Cancer Res. 2000 Mar 1;60(5):1211-6.

19.

Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas.

Tanaka H, Shimada Y, Harada H, Shinoda M, Hatooka S, Imamura M, Ishizaki K.

Cancer Res. 1998 Aug 1;58(15):3429-34.

20.

Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers.

Dallol A, Forgacs E, Martinez A, Sekido Y, Walker R, Kishida T, Rabbitts P, Maher ER, Minna JD, Latif F.

Oncogene. 2002 May 2;21(19):3020-8.

Supplemental Content

Support Center